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Osmoregulation of thirst and vasopressin release in severe chronic renal 
failure. Subjects with severe chronic renal failure (CRF) have higher 
plasma ~oncentrations of arginine vasopressin (A VP) than normal 
subjects , and some develop severe thirst. Eight patients with CRF and 
seven matched controls underwent hypertonic saline infusion to ex-
plore the relationship of thirst and plasma A VP with plasma osmolality . 
Differences in urea concentration between the two groups were con-
trolled for by correcting measured osmolality to a urea of zero. Linear 
regression analysis of the relationships between plasma AVP and thirst 
with plasma osmolality (corrected for urea) was performed. Mean 
results were: control, pAVP = 0.26 (pOsmc - 283.7) versus CRF, 
pAVP = 0.72 (pOsmc - 282.0); and control, thirst = 4.0 (pOsmc -
279.4) versus CRF, thirst = 3.5 (pOsmc - 281.8). The apparent 
sensitivity (slope) of AVP release was greater in severe CRF than in 
normal controls (P = 0.04). There was no significant difference between 
the groups in thirst sensitivity, threshold for thirst onset and threshold 
for AVP release. Osmoregulated thirst 'was normal in severe CRF, but 
increasing osmolality leads to higher concentrations of A VP than would 
be expected. 
In healthy humans, water balance is maintained by the action 
of the antidiuretic hormone arginine vasopressin (A VP) on the 
kidney, and the maintenance of an adequate fluid intake, 
dependent on an intact thirst mechanism. The ability to prevent 
excessive loss of water from the kidney depends on the release 
of adequate amounts of A VP from the posterior pituitary and an 
appropriate response at its site of action, the collecting duct. 
In renal failure, the ability of the kidney to regulate the 
concentration of urine falis with decreasing nephron mass [1]. 
However; even when glomerular filtration rate falls to less than 
5 ml/min, most subjects witlI severe chronic renal failure (CRF) 
main~ain body fluid homeost'asis to a remarkable degree pro-
vided that fluid and solute intake do not vary excessively over 
short periods [2, 3]. Both the concentrating and diluting capac-
ity of the failing kidney are impaired, although the ability to 
concentrate urine tends to diminish earlier [1]. 
Although thirst and A VP are the two most important factors 
controlling water homeostasis in normal man, the role of the 
latter in CRF is not well established. It has been known for a 
number of years that circulating concentrations of A VP are 
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higher in subjects with CRF than in normals [4, 5], and it has 
been suggested that this may predispose to the hyponatremia 
frequently seen in this condition [6, 7]. Most studies examining 
A VP release in CRF have been have peen in hemodialysis 
patients and have reported the effects of reducing plasma 
osmolality on AVP concentration [4, 8, 9]. However, most of 
the change in osmolality seen during dialysis is due to urea 
clearance, and it has been shown that urea does not provide an 
effective osmotic stimulus for A VP release except during acute 
changes in concentration [10]. Thus the high concentrations of 
A VP seen in CRF are not accounted for by excessive urea and 
an alternative explanation must be found. 
Some patients with severe CRF ano particularly those on 
hemodialysis experience excessive thirst, making it difficult to 
adhere to a prescribed fluid restriction. The finding that this 
thirst may be at least partially controlled by angiotensin con~ 
verting enzyme inhibition has prompted a re-examination of this 
aspect of control of water homeostasis [11, 12]. 
In this study we have examined osmon::gulated thirst and 
A VP release in a group of patients with severe CRF using a 
hypertonic saline infusion. This has been shown to be an 
effective osmotic stimulus in different pathological conditions 
as well as in normal subjects [13, 14]. 
Methods 
Patients 
Eight patients (5 male, 3 female; mean age 41.4; range 21 to 59 
years) were recruited from the predialysis clinic (Table 1). 
Underlying renal diseases were: chronic glomerulonephritis (2 
pts), polycystic kidneys (2 pts), chronic pyelonephritis (1 pt) , 
Henoch Schonlein disease (1 pt), hypertensive nephropathy (1 
pt) and unknown etiology (1 pt). No patient had nephrotic 
syndrome or hypoalbuminemia. Diabetic subjects were ex-
cluded from the study in view of the known effects of hypogly-
cemia on vasopressin release [15, 16]. All had end-stage renal 
failure (plasma creatinine 970 ± 78 J.l.mol/liter, mean ± SEM) and 
were studied immediately prior to the commencement of dial-
ysis. No patient had previ04s1y been dialyzed but all had an 
abdominal Tenckhoff catheter in situ to allow the solute and 
volume load to be removed on completion of the study. 
Although two patients had symptoms of exertional angina, none 
had evidence of clinically significant cardiac failure. All bf the 
subjects were on antibypertensive medication and three were 
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Table 1. Clinical characteristics of study subjects 
Age years 
SexM:F 
Creat pmol/liter 
pOSIllc mOsmlliter 
Hematocrit % 
MABPmmHg 
Controls 
N= 7 
41.1 ± 2.5 
6: 1 
95 ± 7 
284.9 ± 0.7 
41 ± 1 
90 ± 2 
Patients 
N= 8 
41.4 ± 3.8 
5:3 
970 ± 78 
286.3 ± 0.9 
29 ± 2 
117 ± 3 
p 
NS 
< 0.001 
NS 
< 0.001 
< 0.001 
Values are mean ± SEM. Abbreviation is: pOsmc ' plasma osmolality 
corrected for plasma urea. 
Table 2. Prescribed medication at the time of patient study 
Subject Diagnosis Drugs 
PKD Atenolol; Nifedipine; Captopril; 
Allopurinol 
2 HNS Labetolol; Furosemide; Quinine sUlphate 
3 PKD Prazosin; I-alpha calcidol; Ranitidiqe; 
Calcium lactate 
4 CGN Atenolol; Methyldopa; Nifedipine; 
Allopurinol 
5 CPN Atenolol 
6 Unk Atenolol; Verapamil; Aluminium 
hydroxide; Calcium lactate 
7 PKD Oxprenolol; Prazosin; Bendroftuazide 
8 HSD Atenolol; Nifedipine; Furosemide 
Abbreviations are: PKD, (adult) polycystic kidney disease; HNS, 
hypertensive nephrosclerosis; CGN, chronic glomerulonephritis; CPN, 
chronic pyelonephritis; Unk, unknown etiology; HSD, Henoch SchOn-
lein disease. 
also taking diuretics. The drugs prescribed to each individual at 
the time' of the study are summarized in Table 2. 
Seven age matched (6 male, 1 female; mean age 41.1 years; 
range 33 to 51 years), healthy controls were recruited from 
hospital and Uniyersity staff. Written consent was obtained for 
the studies, which had been approved by the combined Ethics 
Committee of ' Newcastle Health Authority and the University 
of Newcastle upon Tyne. All subjects were told that the 
infusion might cause local discomfort and thirst. 
Hypertonic saline infusion 
All subjects were fasted from 2200 hours on the night prior to 
the study and forbidden to smoke. Free access to water was 
allowed. Patients with renal failure were prescribed their rou-
tine medication. On the morning of the study, subjects were 
admitted to the Investigation Unit at 0800 and rested supine for 
30 minute~. An indwelling catheter (Braunula, 18G) was in-
serted into an antecul:!ital vein under local ana~sthetic for 
sampling of venous blood. A second cannula (Vepflon, 18G) 
was inserted into the contralateral antecubital fossa for the 
infusion of hypertonic saline. At 0900, a two hour infusion (0.06 
ml/kg/min) of hypertonic (855 mmoVliter) saline was com-
menced according to a Well established protocol [13]. Following 
the study the CRF patients commenced dialysis. 
Samples of venous blood were taken into chilled syringes at 
-15, 0, 30, 60, 90, 120 and 135 minutes and transferred into 
cooled lithium heparin'tubes. One aliquot of each sample was 
kept at 4°C and later analyzed for creatinine, urea and electro-
lytes, osmolality and hematocrit. The plasma from the remain-
der of the sample was immediately separated by centrifugation 
(3000 rpm) at 4°C for 15 minutes, and subsequently stored at 
-70°C for assay of A VP. Thirst was assessed at blood sampling 
times using a well validated visual analogue scale [17], which 
was a modification of that of Rolls etal [18]. Blood pressure was 
measured at five minute intervals using an automatic sphygmo-
manometer (Dynamap 1846 SX, Criticon, USA). The hyper-
tonic saline infusions were well tolerated by the CRF patients 
and normal subjects. 
Analyses 
Packed cell volume was measured in heparinized capillary 
tubes using a Hawkesley microhematocrit centrifuge. Plasma 
osmolality was measured on the day of study by the depression 
of freezing point method (Camlab, UK), and urea and electro-
lyte estimations were performed using an autoanalyzer (Beck-
man Astra). 
Vasopressin was measured within eight weeks of each study 
using a sensitive and specific "in-house" radioimmunoassay 
[19] after magnesiu1l} silicate (Florisil) extraction from plasma. 
The limit of detection was 0.3 pmollliter, intra- and inter-assay 
coefficients of variation at 2 pmoVliter, 9.7% and 15.3%, respec-
tively. 
Thirst ratings 
Thirst was assessed using a visual analogue scale [18]. 
Subjects were presented with an uncalibrated 125 mm long line 
and in response to the question "How thirsty do you feel?", 
were invited to mark the line at the point they considered to 
represent their thirst. Zero mm represented no thirst and 125 
mm, maximal thirst. Thirst rating was defined as the distance in 
mm from zero and this figure used in subsequent analysis. 
Statistics 
Time dependent changes were examined by analysis of 
variance. Paired and unpaired t-tests were used to compare 
group means after ascertaining that the variables were normally 
distributed. 
In both groups, plasma osmolality was corrected for urea by 
subtracting the measured plasma urea from the measured 
plasma osmolality. This allowed direct comparison of osmola-
lity between the two groups. Linear regression by the least 
squares method was then used to derive the relationship for 
each study between plasma arginine vasopressin (pA VP) and 
osmolality corrected for urea (pOsmc), and thirst and pOsmc' 
thus defining the functions (i) pAVP = m (pOsmc - b) and (ii) 
thirst = m (pOsmc - b), where "m" is the slope, or sensitivity 
and "b" is the abscissal intercept. All values are mean ± SEM. 
Results 
The effects of the hypertonic saline infusion on plasma 
osmolality, A VP, thirst, hematocrit and mean arterial blood 
pressure are summarized in Table 3 and the data for changes in 
thirst and plasma A VP with osmolality are shown in Figure 2. 
Changes of osmolality, A VP and thirst with time are shown in 
Figure 1. 
Baseline hematocrits were significantly different between the 
control and patient groups (control 41 ± 1 vs. CRF 29 ± 2%, P 
< 0.(01). The hematocrit decreased during the infusion to a 
slightly greater extent in the control group (Table 3). However, 
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Table 3. Plasma osmolality, A VP, thirst, hematocrit and mean 
arterial blood pressure before and 15 minutes following a 2 hour 
infusion of hypertonic saline (855 mmo]lliter, 0.06 mllkg/min) 
Controls Patients 
N= 7 N= 8 
pOsmc pre 284.9 ± 0.7 286.3 ± 0.9 
mOsmlkg post 302.1 ± 1.5 305.5 ± 1.4 
AVP pre 0.5 ± 0.1 3.5 ± 0.9 
pmoilliter post 4.9 ± 0.6 7.5 ± 3.7 
Thirst mm pre 23 ± 3 15 ± 4 
post 88 ± II 80 ± 10 
Hct% pre 41 ± 1 29 ± 2 
post 37 ± 2 27 ± 2 
MABPmmHg pre 90 ± 2 117 ± 3 
post 90 ± 4 123 ± 4 
Values are mean ± SEM. 
the calculated change in blood volume for each subject during 
the infusion was similar in each group (control 10.6 ± 0.74 vs. 
CRF 8.5 ± 1.00%, NS). 
Plasma osmolality 
Changes in plasma osmolality (corrected for blood urea) 
during the saline infusion in the two groups are shown in Figure 
lA and Table 3. There was a significant linear increase in 
osmolality in both groups (P < 0.001), but there were no 
significant differences at any of the time points. 
Plasma AVP 
Changes in plasma A VP concentration in the two groups 
during the infusion are shown in Figure 1B and Table 3. There 
was a significant linear increase in plasma A VP concentration in 
both groups (P < 0.001), and plasma AVP (;oncentrations were 
significantly higher in the CRF patients at all time points. 
Thirst 
Thirst increased in both groups during the infusion (Fig. lC, 
Table 3). There was a significant linear increase in thirst in both 
groups (P < 0.001). There were no significant differences 
between the two groups. 
A VP and osmolality 
The relationship between plasma A VP and corrected plasma 
osmolality, calculated by linear regression analysis is shown for 
each subject in Table 4. There was no significant difference in 
the intercept of the mean regression lines for CRF and control 
subjects [control, pAVP = 0.26 (pOsmc - 283.7); CRF, pAVP 
= 0.72 (pOsmc - 282.0)], but the slope was significantly greater 
in CRF patients (CRF, 0.72 ± 0.18 vs. control, 0.26 ± 0.04 
pmol/liter/mOsmollkg; P = 0.04). One subject (#7) had a slope 
that was more than twice that of any other subject. No reason 
for this was found. If the data from this subject is eliminated, 
the average slope in the CRF group becomes 0.54 ± 0.07 (P = 
0.008 cf control). 
Thirst and osmolality 
The relationship between thirst and corrected plasma osmo-
lality is shown for each subject in Table 4. There was no 
significant difference in the mean regression lines for CRF and 
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Fig. 1. Mean responses of plasma osmolality, plasma vasopressin and 
thirst to hypertonic saline infusion. SEM for each point is marked. 
Infusion ran from 0 to 120 minutes. Detection limit of AVP assay is 0.3 
pmolliiter. Symbols are: (-......-.) normal; (0--0) ESRF; (*) P < 
0.005; **P < 0.001. 
control subjects [control, thirst = 3.97 (pOsmc - 279.4); CRF, 
thirst = 3.48 (pOsmc - 281.8)]. 
Discussion 
The results demonstrate that in severe renal failure, plasma 
A VP response to an osmotic stimulus is apparently enhanced as 
compared to normal subjects. However, the threshold osmola-
lity at which vasopressin begins to be secreted is virtually 
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Fig. 2. Relationships between plasma vasopressin and plasma osmolality and between thirst mid plasma osmolality during hypertonic saline 
infusion. Detection limit in our radioimmunoassay is 0.3 pmol/liter. Symbols are: (e) normal; (0) ESRF. 
identiCal in the two groups. This provides good evidence that 
the osmoreceptor thought to control vasopressin release main-
tains its normal "set point" in advanced renal impairment. 
The cause of the increased slope, or apparent sensitivity of 
vasopressin accumulation is not established in this study. 
Certainly these findings do not confirm or refute the possibility 
that there is enhanced A VP secretion from osmotic stimulation 
in CRF, as the concentration of AVP measured in any individ-
ual represents the summation of release and clearance of the 
hormone. Since the relative clearance rates of the two groups 
are not known, it is not possible to determine actual release 
rates of A VP. 
The most likely explanation for the elevated concentrations 
found in CRF is the loss of clearance of A VP by the failing 
kidneys. A previous study has suggested that the kidney is 
normally responsible for approximately 60 to 70% of A VP clear~ 
ance [20], with the remainder being cleared by the liver and gut 
vasculature. Metabolic clearance rate of vasopressin has been 
determined in normal pregnant subjects and shown to be en-
hanced [21]. This correlates well with the known decrease in the 
slope of A VP release to an osmotic stimulus in these subjects. 
We have previously shown that the immunoreactive AVP 
measured in chronic renal failure by radioimmunoassay in our 
laboratory coelutes with both synthetic A VP and A VP from 
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Table 4. The slope (m), abscissal intercept (b) and correlation coefficient (r) for the relationship in each subject between AVP and osmolality 
and thirst and osmolality 
Controls (N = 7) 
Subject m b 
AVP 
1 0.35 286.3 
2 0.18 283.9 
3 0.29 286.7 
4 0.19 278.8 
5 0.21 281.2 
6 0.47 287.5 
7 0.15 281.2 
8 
Mean 0.26 283.7 
SEM 0.04 1.3 
Thirst 
1 2.19 275.2 
2 1.53 276.4 
3 5.91 281.8 
4 4.28 270.2 
5 5.14 282.3 
6 4.10 287.5 
7 4.65 282.6 
8 
Mean 3.97 279.4 
SEM 0.59 2.2 
a p = 0.04 compared to control. 
normal subjects [22]. As such, it is very unlikely that the high 
concentrations measured here are due to non-specific interler-
ence in the assay by circulating substances accumulating in 
renal failure. 
Other possibilities to account for the higher concentrations of 
A VP include continued non-osmotic release of the hormone due 
to hypovolemia [23], nausea [24], or drug interlerence. Alter-
natively, it is conceivable that a substance accumulates in CRF 
that is capable of directly enhancing the sensitivity of the 
hypothalamus to an osmotic stimulus. 
In the subjects studied, there was no clinical evidence of 
hypovolemia such as postural hypotension or low central 
venous pressure as determined by inspection of the internal 
jugular veins. However, subclinical degrees of hypovolemia 
could not be excluded. An objective measure of blood volume, 
such as determination of plasma or red cell volume, was 
impractical in this study, and the range of drugs taken by the 
subjects would render plasma renin concentration (as an indi-
rect marker of blood volume) uninterpretable due to the known 
direct effects of diuretics and beta blockers on renin release [25, 
26]. In healthy humans, the presence of hypovolemia in the 
absence of hypotension may increase the slope of vasopressin 
release to an osmotic stimulus, but this is associated with a 
downward resetting of the threshold for vasopressin release 
[27]. Although studies in rats have suggested that slight degrees 
of hypovolemia can increase sensitivity without affecting the 
threshold [28], in humans, this aspect of osmoregulatory func-
tion does not seem to be affected by small acute changes in 
blood volume [29]. The effect of possible undetected chronic 
hypovolemia in these subjects with renal failure cannot be 
positively eliminated. 
No patient complained of nausea during the studies, and it is 
in any case unlikely that nausea would cause enhancement of 
Patients (N = 8) 
r m b r 
0.97 0.44 282.3 0.97 
0.97 0.36 279.5 0.98 
0.99 0.63 281.4 0.99 
0.95 0.31 286.8 0.95 
0.98 0.73 281.3 0.99 
0.97 0.82 283.9 0.97 
0.97 1.93 290.6 0.99 
0.50 270.5 0.94 
0.97 0.72" 282.0 0.97 
0.01 0.18 2.1 o.ot 
0.92 3.24 283.9 0.98 
0.98 5.42 280.7 0.96 
0.98 4.93 281.0 0.94 
0.95 2.25 287.6 0.99 
0.93 2.34 267.6 0.96 
0.94 1.66 285.7 0.98 
0.97 3.81 289.5 0.98 
4.19 278.8 0.98 
0.95 3.48 281.8 0.97 
0.02 0.48 2.4 0.01 
release of AVP to an osmotic stimulus; more commonly the 
onset of nausea causes a substantial rise in plasma vasopressin 
at that time [24]. 
Thirst perception was found to be remarkably similar in both 
groups. Despite the clinical observation that some patients, 
partiCUlarly those on hemodialysis, become excessively thirsty, 
only one subject in the renal failure group (subject 5) had 
evidence of an abnormally low set point for onset of thirst. 
Although this study does not therefore confirm the clinical 
impression of increased thirst in CRF, further studies using 
larger numbers of subjects may identify a subgroup of thirsty 
patients in whom a cause may be identifiable. 
The theoretical osmolar thresholds for vasopressin release 
and thirst onset that we have calculated from our data are very 
close in both groups of subjects. This is in agreement with 
previous work from this laboratory [30]. Other workers have 
proposed that the thirst threshold is much higher than the A VP 
secretion threshold. However, these findings are not strictly 
comparable, since they have defined thirst threshold as an 
absolute sensation occurring at plasma osmolalities of 295 to 
300 mOsmllkg [13, 31], and in those studies in which a visual 
analogue scale was used [18, 32], a zero thirst rating was 
ascribed to each subject before the start of the experiments, 
thereby prejudging thirst appreciation at that time. As such, 
none of these studies allowed examination of a true osmotic 
threshold for thirst onset. 
The findings of this study suggest that the hypothalamic 
osmoreceptors for thirst and vasopressin release continue to 
function in a coordinated fashion in severe chronic renal failure. 
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